Learn More
Description
The M17/4 antibody reacts with the 180 kDa αL chain of LFA-1 (CD11a/CD18, αLβ2 integrin), a heterodimeric surface glycoprotein expressed on almost all leukocytes. CD8a+CD8b- intestinal intraepithelial T lymphocytes, which are believed to be thymus independent, do not express CD11a. LFA-1 mediates a variety of heterotypic and homotypic intercellular adhesions through interaction with ICAM-1 (CD54) and ICAM-2 (CD102), including participation in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. mAb M17/4 blocks a variety of LFA-1-mediated cells interactions in vitro, and costimulatory effects have also been described. In vivo treatment with M17/4 mAb reduces the severity of graft-versus-host reactions, prolongs allograft survival, inhibits the development of autoimmunity, and blocks substance P-induced leukocyte migration. The M17/4 and 2D7 (Cat. No. 553120) antibodies are reported to recognize different epitopes of the CD11a molecule.
Specifications
Specifications
| Antigen | CD11a |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Clone | M17/4 |
| Conjugate | R718 |
| Host Species | Mouse |
| Quantity | 50 μg |
| Regulatory Status | RUO |
| Primary or Secondary | Primary |
| Target Species | Mouse |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.